Potassium channels, renal fibrosis, and diabetes

Diabetes

Volumn 62, Issue 8, 2013, Pages 2648-2650

  Menè, Paolo ^a,b   Pirozzi, Nicola ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; COLLAGEN; MITOGEN ACTIVATED PROTEIN KINASE; POTASSIUM CHANNEL KCA3.1; POTASSIUM CHANNEL KCNN4; POTASSIUM CHANNEL SK4; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; UNCLASSIFIED DRUG; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; KCNN4 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

CALCIUM TRANSPORT; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME PHOSPHORYLATION; EXTRACELLULAR CALCIUM; FIBROBLAST; FIBROGENESIS; GENE EXPRESSION; HUMAN; KIDNEY FIBROSIS; KIDNEY FUNCTION; NONHUMAN; NOTE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION; ANIMAL; DRUG ANTAGONISM; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOLOGY; ANTAGONISTS AND INHIBITORS; DIABETIC NEPHROPATHIES;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; HUMANS; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; PYRAZOLES; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84891688447     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0603     Document Type: Note

References (21)

1. Neilson EG. Mechanisms of disease: fibroblasts - a new look at an old problem. Nat Clin Pract Nephrol 2006;2:101-108
2. Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol 2006;17:2992-2998
3. Kolset SO, Reinholt FP, Jenssen T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem 2012;60:976-986
4. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008;19:2282-2287
5. Boor P, Sebeková K, Ostendorf T, Floege J. Treatment targets in renal fibrosis. Nephrol Dial Transplant 2007;22:3391-3407
6. Bonventre JV. Can we target tubular damage to prevent renal function decline in diabetes? Semin Nephrol 2012;32:452-462
7. Begenisich T, Nakamoto T, Ovitt CE, et al. Physiological roles of the intermediate conductance, Ca2+-activated potassium channel Kcnn4. J Biol Chem 2004;279:47681-47687
8. Tao R, Lau CP, Tse HF, Li GR. Regulation of cell proliferation by intermediate-conductance Ca2+-activated potassium and volume-sensitive chloride channels in mouse mesenchymal stem cells. Am J Physiol Cell Physiol 2008;295:C1409-C1416
9. Toyama K, Wulff H, Chandy KG, et al. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest 2008;118:3025-3037
10. Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes. J Immunol 2007;179:4563-4570
11. Albaqumi M, Srivastava S, Li Z, et al. KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int 2008;74: 740-749
12. Grgic I, Kiss E, Kaistha BP, et al. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci U S A 2009; 106:14518-14523
13. Menè P, Pirozzi N. Potassium channels: the 'master switch' of renal fibrosis? Nephrol Dial Transplant 2010;25:353-355
14. Huang C, Shen S, Ma Q, et al. Blockade of KCa3.1 ameliorates renal fibrosis through the TGF-b1/Smad pathway in diabetic mice. Diabetes 2013;62:2923-2934
15. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1- induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003;9:964-968
16. Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008;19:12-23
17. Yang J, Dai C, Liu Y. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002;13:2464-2477
18. Wang LP, Wang Y, Zhao LM, Li GR, Deng XL. Angiotensin II upregulates KCa3.1 channels and stimulates cell proliferation in rat cardiac fibroblasts. Biochem Pharmacol 2013;85:1486-1494
19. Zhao LM, Zhang W, Wang LP, Li GR, Deng XL. Advanced glycation end products promote proliferation of cardiac fibroblasts by upregulation of KCa3.1 channels. Pflugers Arch 2012;464:613-621
20. Zhao LM, Su XL, Wang Y, Li GR, Deng XL. KCa3.1 channels mediate the increase of cell migration and proliferation by advanced glycation endproducts in cultured rat vascular smooth muscle cells. Lab Invest 2013;93:159-167
21. Wulff H, Köhler R. Endothelial small-conductance and intermediateconductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets. J Cardiovasc Pharmacol 2013;61:102-112